Vision improves in dry AMD after photobiomodulation treatment
Click Here to Manage Email Alerts
Results from a pilot study showed the effectiveness of LumiThera’s Valeda Light Delivery System in patients with dry age-related macular degeneration.
The photobiomodulation (PBM) treatment system is intended to combat ocular damage and disease and prevent vision loss, the company said in a press release.
Data from the pilot study ELECTROLIGHT demonstrated the treatment’s effectiveness after examining the functional vision of 15 individuals (aged 65-93 years) using a Diopsys electroretinogram device. Researchers tested participants’ vision weekly before each Valeda treatment session; follow-up was conducted for 6 months.
One month after initial PBM treatment, multi-luminance ERG improved by 14.4%, and there was a positive correlation between multi-luminance ERG and fixed luminance as well as chromatic ERG outcomes, according to the release.
The study results also showed that there was a 12.8 ± .98 letter improvement in best corrected visual acuity and Mars Contrast Sensitivity among participants after 6 months of treatment.
“We are strong supporters of treating degenerative disease early to slow the progression of vision-threatening disease,” LumiThera President and CEO Clark E. Tedord, PhD, said in the release.
“Diopsys ERG testing is a powerful and quantitative diagnostic that can be coupled with LumiThera’s PGM treatments to characterize early patient benefits on visual function,” Diopsys CEO Joe Fontanetta said in the release. “These results of this work will allow physicians to diagnose, treat and monitor patients and provides physicians a solution for a disease with limited treatment options.”
Read more about
Click Here to Manage Email Alerts